Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448102 | 1.00 | CASP3 (0.49) | CASP3PTPN1KMT2AMDM4TP53 | |
| SCHEMBL3039215 | 0.86 | CASP3 (0.57) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL29664082 | 0.86 | CASP3 (0.57) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL8355967 | 0.86 | CASP3 (0.57) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL13323320 | 0.86 | CASP3 (0.57) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL117946 | 0.85 | MDM4 (0.51) | CASP3PTPN1MDM4TP53MDM2 | |
| SCHEMBL29349956 | 0.85 | MDM4 (0.51) | CASP3PTPN1MDM4TP53MDM2 | |
| SCHEMBL119588 | 0.85 | MDM4 (0.51) | CASP3PTPN1MDM4TP53MDM2 | |
| SCHEMBL16075059 | 0.85 | PTPN1 (0.49) | PTPN1MDM4TP53MDM2 | |
| SCHEMBL31714182 | 0.85 | MDM4 (0.51) | CASP3PTPN1MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119951435-A | Continuous flow synthesizer and application method | 海南建邦制药科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-118105510-A | Preparation and application of polypeptide self-assembled nano-drug carrier targeting cGAS-STING signal pathway | 首都医科大学附属北京儿童医院 | 2024-05-31 | — | — | CN | claimed |
| CN-114539358-B | Polypeptide, preparation method and application | 中国科学院大连化学物理研究所 | 2023-09-15 | — | — | CN | claimed |
| CN-115894630-A | Preparation method of linaclotide | 四川轻化工大学 | 2023-04-04 | — | — | CN | claimed |
| CN-114539358-A | Polypeptide, preparation method and application | 中国科学院大连化学物理研究所 | 2022-05-27 | — | — | CN | claimed |
| CN-122028898-A | Novel short-chain peptides and derivatives thereof | 艾缇亚(上海)制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-04-30 | — | — | US | disclosed |
| EP-4700039-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | Winkey Technology USA Inc (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049103-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | WINKEY TECH USA INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2026-01-20 | — | — | US | disclosed |
| WO-2025264177-A1 | METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2025-12-26 | — | — | WO | disclosed |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | ZHEJIANG PEPTITES BIOTECH CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-3986914-A1 | CONSTRAINED PEPTIDES | TearSolutions, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-113956333-B | Synthesis and purification method of linaclotide | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114245800-A | Melanocyte regulatory peptides | IDP研发制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-22 | — | — | US | disclosed |
| CN-114206916-A | Restricted peptides | 缇尔索卢森公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114195855-A | Solid-phase synthesis method for polypeptide containing three pairs of disulfide bonds by introducing one pair of disulfide bonds | 深圳翰宇药业股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220082553-A1 | PATIENT SELECTION METHOD FOR INFLAMMATION | PURDUE RESEARCH FOUNDATION | 2022-03-17 | — | — | US | disclosed |
| CN-113956333-A | Synthesis and purification method of linaclotide | 浙江湃肽生物有限公司南京分公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049103-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | ARG1, ARGLU1, ARG2 | CASP3 2030/4885PTPN1 1340/4885KMT2A 3031/4885 |
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | SCN8A, SCN9A, VIP | CASP3 994/4885PTPN1 3325/4885KMT2A 1633/4885 |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | TP53, MDM2, MDM4 | CASP3 2615/4885PTPN1 1902/4885KMT2A 3182/4885 |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | SEM1, REN, SETDB1 | CASP3 4261/4885PTPN1 2024/4885KMT2A 431/4885 |
| US-20220082553-A1 | PATIENT SELECTION METHOD FOR INFLAMMATION | FOLH1, FOLR2, TNF | CASP3 1091/4885PTPN1 4474/4885KMT2A 4103/4885 |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VIP, MLEC, SEC16A | CASP3 1344/4885PTPN1 4052/4885KMT2A 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.